World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2024 April 15; 16(4): 1091-1675





Published by Baishideng Publishing Group Inc

World Journal of Gastrointestinal Oncology

Contents

Monthly Volume 16 Number 4 April 15, 2024

EDITORIAL

1091	Parallel pathways: A chronicle of evolution in rectal and breast cancer surgery <i>Pesce A, Fabbri N, Iovino D, Feo CV</i>
1097	Hepatitis B virus genotypes in precision medicine of hepatitis B-related hepatocellular carcinoma: Where we are now Sukowati CHC, Jayanti S, Turyadi T, Muljono DH, Tiribelli C
	REVIEW
1104	Novel milestones for early esophageal carcinoma: From bench to bed
	Qi JH, Huang SL, Jin SZ
1119	Colorectal cancer screening: A review of current knowledge and progress in research
	Lopes SR, Martins C, Santos IC, Teixeira M, Gamito É, Alves AL
1134	New avenues for the treatment of immunotherapy-resistant pancreatic cancer
	Silva LGO, Lemos FFB, Luz MS, Rocha Pinheiro SL, Calmon MDS, Correa Santos GL, Rocha GR, de Melo FF
	MINIREVIEWS
1154	Present situation of minimally invasive surgical treatment for early gastric cancer
	Li CY, Wang YF, Luo LK, Yang XJ
1166	Mixed neuroendocrine non-neuroendocrine neoplasms in gastroenteropancreatic tract
	Díaz-López S, Jiménez-Castro J, Robles-Barraza CE, Ayala-de Miguel C, Chaves-Conde M
1180	Esophageal cancer screening, early detection and treatment: Current insights and future directions
1100	Qu HT, Li Q, Hao L, Ni YJ, Luan WY, Yang Z, Chen XD, Zhang TT, Miao YD, Zhang F
	ORIGINAL ARTICLE
	Retrospective Cohort Study
1192	Pre-operative enhanced magnetic resonance imaging combined with clinical features predict early
	recurrence of hepatocellular carcinoma after radical resection Chen JP, Yang RH, Zhang TH, Liao LA, Guan YT, Dai HY
	Cren 91, Tung MI, Enung 111, Eluo EA, Ouun 11, Dui 111
1204	Clinical analysis of multiple primary gastrointestinal malignant tumors: A 10-year case review of a single-

Zhu CL, Peng LZ

center



Contents

World Journal of Gastrointestinal Oncology

Monthly Volume 16 Number 4 April 15, 2024

Retrospective Study

1213 Predictive model for non-malignant portal vein thrombosis associated with cirrhosis based on inflammatory biomarkers

Nie GL, Yan J, Li Y, Zhang HL, Xie DN, Zhu XW, Li X

1227 Predictive modeling for postoperative delirium in elderly patients with abdominal malignancies using synthetic minority oversampling technique

Hu WJ, Bai G, Wang Y, Hong DM, Jiang JH, Li JX, Hua Y, Wang XY, Chen Y

Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus 1236 programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma

Ma KP, Fu JX, Duan F, Wang MQ

1248 Should we perform sigmoidoscopy for colorectal cancer screening in people under 45 years? Leong W, Guo JQ, Ning C, Luo FF, Jiao R, Yang DY

1256 Computed tomography-based radiomics diagnostic approach for differential diagnosis between early- and late-stage pancreatic ductal adenocarcinoma

Ren S, Qian LC, Cao YY, Daniels MJ, Song LN, Tian Y, Wang ZQ

1268 Prognostic analysis of related factors of adverse reactions to immunotherapy in advanced gastric cancer and establishment of a nomogram model

He XX, Du B, Wu T, Shen H

Clinical Trials Study

1281 Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers

Bao ZH, Hu C, Zhang YQ, Yu PC, Wang Y, Xu ZY, Fu HY, Cheng XD

Observational Study

1296 Computed tomography radiogenomics: A potential tool for prediction of molecular subtypes in gastric stromal tumor

Yin XN, Wang ZH, Zou L, Yang CW, Shen CY, Liu BK, Yin Y, Liu XJ, Zhang B

1309 Application of texture signatures based on multiparameter-magnetic resonance imaging for predicting microvascular invasion in hepatocellular carcinoma: Retrospective study

Nong HY, Cen YY, Qin M, Qin WQ, Xie YX, Li L, Liu MR, Ding K

- 1319 Causal roles of gut microbiota in cholangiocarcinoma etiology suggested by genetic study Chen ZT, Ding CC, Chen KL, Gu YJ, Lu CC, Li QY
- 1334 Is recovery enhancement after gastric cancer surgery really a safe approach for elderly patients? Li ZW, Luo XJ, Liu F, Liu XR, Shu XP, Tong Y, Lv Q, Liu XY, Zhang W, Peng D
- 1344 Establishment of a cholangiocarcinoma risk evaluation model based on mucin expression levels Yang CY, Guo LM, Li Y, Wang GX, Tang XW, Zhang QL, Zhang LF, Luo JY



Contor	World Journal of Gastrointestinal Oncology
Conten	Monthly Volume 16 Number 4 April 15, 2024
1361	Effectiveness of fecal DNA syndecan-2 methylation testing for detection of colorectal cancer in a high-risk Chinese population
	Luo WF, Jiao YT, Lin XL, Zhao Y, Wang SB, Shen J, Deng J, Ye YF, Han ZP, Xie FM, He JH, Wan Y
	Clinical and Translational Research
1374	Clinical and socioeconomic determinants of survival in biliary tract adenocarcinomas
	Sahyoun L, Chen K, Tsay C, Chen G, Protiva P
1384	Risk factors, prognostic factors, and nomograms for distant metastasis in patients with diagnosed duodenal cancer: A population-based study
	Shang JR, Xu CY, Zhai XX, Xu Z, Qian J
1421	NOX4 promotes tumor progression through the MAPK-MEK1/2-ERK1/2 axis in colorectal cancer
	Xu YJ, Huo YC, Zhao QT, Liu JY, Tian YJ, Yang LL, Zhang Y
	Basic Study
1437	Curcumin inhibits the growth and invasion of gastric cancer by regulating long noncoding RNA AC022424.2
	Wang BS, Zhang CL, Cui X, Li Q, Yang L, He ZY, Yang Z, Zeng MM, Cao N
1453	MicroRNA-298 determines the radio-resistance of colorectal cancer cells by directly targeting human dual- specificity tyrosine(Y)-regulated kinase 1A
	Shen MZ, Zhang Y, Wu F, Shen MZ, Liang JL, Zhang XL, Liu XJ, Li XS, Wang RS
1465	Human β -defensin-1 affects the mammalian target of rapamycin pathway and autophagy in colon cancer cells through long non-coding RNA TCONS_00014506
	Zhao YX, Cui Y, Li XH, Yang WH, An SX, Cui JX, Zhang MY, Lu JK, Zhang X, Wang XM, Bao LL, Zhao PW
1479	FAM53B promotes pancreatic ductal adenocarcinoma metastasis by regulating macrophage M2 polarization
	Pei XZ, Cai M, Jiang DW, Chen SH, Wang QQ, Lu HM, Lu YF
1500	Transcriptome sequencing reveals novel biomarkers and immune cell infiltration in esophageal tumori- genesis
	Sun JR, Chen DM, Huang R, Wang RT, Jia LQ
1514	Construction of CDKN2A-related competitive endogenous RNA network and identification of GAS5 as a prognostic indicator for hepatocellular carcinoma
	Pan Y, Zhang YR, Wang LY, Wu LN, Ma YQ, Fang Z, Li SB
1532	Two missense <i>STK11</i> gene variations impaired LKB1/adenosine monophosphate-activated protein kinase signaling in Peutz-Jeghers syndrome
	Liu J, Zeng SC, Wang A, Cheng HY, Zhang QJ, Lu GX
1547	Long noncoding RNAs HAND2-AS1 ultrasound microbubbles suppress hepatocellular carcinoma progression by regulating the miR-873-5p/tissue inhibitor of matrix metalloproteinase-2 axis
	Zou Q, Wang HW, Di XL, Li Y, Gao H

	World Journal of Gastrointestinal Oncology
Conte	nts Monthly Volume 16 Number 4 April 15, 2024
1564	Upregulated lncRNA PRNT promotes progression and oxaliplatin resistance of colorectal cancer cells by regulating HIPK2 transcription
	Li SN, Yang S, Wang HQ, Hui TL, Cheng M, Zhang X, Li BK, Wang GY
	SYSTEMATIC REVIEWS
1578	Prognosis value of heat-shock proteins in esophageal and esophagogastric cancer: A systematic review and meta-analysis
	Nakamura ET, Park A, Pereira MA, Kikawa D, Tustumi F
1596	Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review
	Farooq HZ, James M, Abbott J, Oyibo P, Divall P, Choudhry N, Foster GR
	META-ANALYSIS
1613	Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers
	Zhang XM, Yang T, Xu YY, Li BZ, Shen W, Hu WQ, Yan CW, Zong L
1626	Success rate of current human-derived gastric cancer organoids establishment and influencing factors: A systematic review and meta-analysis
	Jiang KL, Wang XX, Liu XJ, Guo LK, Chen YQ, Jia QL, Yang KM, Ling JH
	CASE REPORT
1647	Pathologically successful conversion hepatectomy for advanced giant hepatocellular carcinoma after multidisciplinary therapy: A case report and review of literature
	Chu JH, Huang LY, Wang YR, Li J, Han SL, Xi H, Gao WX, Cui YY, Qian MP
1660	Clinical pathological characteristics of "crawling-type" gastric adenocarcinoma cancer: A case report
	Xu YW, Song Y, Tian J, Zhang BC, Yang YS, Wang J
1668	Primary pancreatic peripheral T-cell lymphoma: A case report
	Bai YL, Wang LJ, Luo H, Cui YB, Xu JH, Nan HJ, Yang PY, Niu JW, Shi MY



Contents

World Journal of Gastrointestinal Oncology

Monthly Volume 16 Number 4 April 15, 2024

ABOUT COVER

Peer Reviewer of World Journal of Gastrointestinal Oncology, Lie Zheng, Director, Professor, Department of Gastroenterology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi'an 730000, Shaanxi Province, China. xinliwen696@126.com

AIMS AND SCOPE

The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING

The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJGO as 3.0; IF without journal self cites: 2.9; 5-vear IF: 3.0; Journal Citation Indicator: 0.49; Ranking: 157 among 241 journals in oncology; Quartile category: Q3; Ranking: 58 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2022 is 4.1 and Scopus CiteScore rank 2022: Gastroenterology is 71/149; Oncology is 197/366.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Xiang-Di Zhang; Production Department Director: Xiang Li; Cover Editor: Jia-Ru Fan.

NAME OF JOURNAL World Journal of Gastrointestinal Oncology	INSTRUCTIONS TO AUTHORS https://www.wjgnet.com/bpg/gerinfo/204
ISSN ISSN 1948-5204 (online)	GUIDELINES FOR ETHICS DOCUMENTS
LAUNCH DATE February 15, 2009	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH https://www.wignet.com/bpg/gerinfo/240
FREQUENCY Monthly	PUBLICATION ETHICS https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF Monjur Ahmed, Florin Burada	PUBLICATION MISCONDUCT https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/1948-5204/editorialboard.htm PUBLICATION DATE	https://www.wjgnet.com/bpg/gerinfo/242 STEPS FOR SUBMITTING MANUSCRIPTS
April 15, 2024 COPYRIGHT	https://www.wjgnet.com/bpg/GerInfo/239 ONLINE SUBMISSION
© 2024 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: office@baishideng.com https://www.wjgnet.com



WĴ

O World Journal of *Gastrointestinal* Oncolor Oncology

Submit a Manuscript: https://www.f6publishing.com

World J Gastrointest Oncol 2024 April 15; 16(4): 1309-1318

DOI: 10.4251/wjgo.v16.i4.1309

Observational Study

ISSN 1948-5204 (online)

ORIGINAL ARTICLE

Application of texture signatures based on multiparameter-magnetic resonance imaging for predicting microvascular invasion in hepatocellular carcinoma: Retrospective study

Hai-Yang Nong, Yong-Yi Cen, Mi Qin, Wen-Qi Qin, You-Xiang Xie, Lin Li, Man-Rong Liu, Ke Ding

Specialty type: Oncology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B Grade C (Good): 0 Grade D (Fair): 0 Grade E (Poor): 0

P-Reviewer: Hosmane NS, United States

Received: October 30, 2023 Peer-review started: October 30, 2023 First decision: December 5, 2023 Revised: December 18, 2023 Accepted: February 5, 2024

Article in press: February 5, 2024 Published online: April 15, 2024



Hai-Yang Nong, Mi Qin, Wen-Qi Qin, You-Xiang Xie, Ke Ding, Department of Radiology, The Third Affiliated Hospital of Guangxi Medical University, Nanning 530031, Guangxi Zhuang Autonomous Region, China

Hai-Yang Nong, Department of Radiology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China

Yong-Yi Cen, Department of Radiology, The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Nanning 530031, Guangxi Zhuang Autonomous Region, China

Lin Li, Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Guangxi Medical University, Nanning 530031, Guangxi Zhuang Autonomous Region, China

Man-Rong Liu, Department of Ultrasound, The Third Affiliated Hospital of Guangxi Medical University, Nanning 530031, Guangxi Zhuang Autonomous Region, China

Corresponding author: Ke Ding, MD, Doctor, Department of Radiology, The Third Affiliated Hospital of Guangxi Medical University, No. 13 Dancun Road, Nanning 530031, Guangxi Zhuang Autonomous Region, China. 272480365@qq.com

Abstract

BACKGROUND

Despite continuous changes in treatment methods, the survival rate for advanced hepatocellular carcinoma (HCC) patients remains low, highlighting the importance of diagnostic methods for HCC.

AIM

To explore the efficacy of texture analysis based on multi-parametric magnetic resonance (MR) imaging (MRI) in predicting microvascular invasion (MVI) in preoperative HCC.

METHODS

This study included 105 patients with pathologically confirmed HCC, categorized into MVI-positive and MVI-negative groups. We employed Original Data Analysis, Principal Component Analysis, Linear Discriminant Analysis (LDA), and Non-LDA (NDA) for texture analysis using multi-parametric MR images to



WJGO | https://www.wjgnet.com

predict preoperative MVI. The effectiveness of texture analysis was determined using the B11 program of the MaZda4.6 software, with results expressed as the misjudgment rate (MCR).

RESULTS

Texture analysis using multi-parametric MRI, particularly the MI + PA + F dimensionality reduction method combined with NDA discrimination, demonstrated the most effective prediction of MVI in HCC. Prediction accuracy in the pulse and equilibrium phases was 83.81%. MCRs for the combination of T2-weighted imaging (T2WI), arterial phase, portal venous phase, and equilibrium phase were 22.86%, 16.19%, 20.95%, and 20.95%, respectively. The area under the curve for predicting MVI positivity was 0.844, with a sensitivity of 77.19% and specificity of 91.67%.

CONCLUSION

Texture analysis of arterial phase images demonstrated superior predictive efficacy for MVI in HCC compared to T2WI, portal venous, and equilibrium phases. This study provides an objective, non-invasive method for preoperative prediction of MVI, offering a theoretical foundation for the selection of clinical therapy.

Key Words: Magnetic resonance imaging; Hepatocellular carcinoma; Texture analysis; Microvascular invasion

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Texture analysis using arterial phase images provides superior predictive efficacy for microvascular invasion (MVI) in hepatocellular carcinoma (HCC) compared to T2-weighted imaging, portal venous, and equilibrium phases. The texture analysis of liver magnetic resonance images holds significant value for the preoperative prediction of MVI in HCC patients.

Citation: Nong HY, Cen YY, Qin M, Qin WQ, Xie YX, Li L, Liu MR, Ding K. Application of texture signatures based on multiparameter-magnetic resonance imaging for predicting microvascular invasion in hepatocellular carcinoma: Retrospective study. *World J Gastrointest Oncol* 2024; 16(4): 1309-1318

URL: https://www.wjgnet.com/1948-5204/full/v16/i4/1309.htm **DOI:** https://dx.doi.org/10.4251/wjgo.v16.i4.1309

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide[1]. Currently, the optimal treatment for liver cancer remains radical resection. However, many patients miss the opportunity for curative surgery at the time of diagnosis. Despite the availability of treatments for advanced, unresectable HCC, such as transcatheter arterial chemoembolization, radiofrequency thermal ablation, and molecular targeted drugs (including tyrosine kinase inhibitors like sorafenib and lovatinib), their efficacy remains limited[2]. Thus, there is an urgent need for more effective diagnostic methods to detect the disease status of patients early and enhance their survival rates.

Microvascular invasion (MVI) is a crucial risk factor influencing tumor relapse post-surgery [3-5]. Accurate pre-surgery prediction of MVI influences the selection of tumor treatment plans. Currently, the assessment of HCC MVI primarily depends on postoperative pathological biopsies; however, this method is invasive and carries risks like bleeding, tumor implantation, and metastasis. Image texture analysis offers an objective and quantitative means of image description. The local characteristics of image pixel gray values, their changing patterns, and distribution, as quantitatively analyzed, can reflect the physiological heterogeneity within the region of interest (ROI). Recently, it has been applied in a range of medical imaging techniques to aid in disease diagnosis and treatment^[6-9]. Previous studies have indicated that computed tomography (CT) imaging is the principal method for texture analysis in predicting MVI in HCC[10,11], with most studies opting for 2D ROIs. Compared to 3D ROIs, these studies lacked comprehensive assessment of tumor heterogeneity [12-14]. Furthermore, the software, analysis, and discrimination methods used in medical imaging texture analysis vary. Texture analysis is widely used to predict disease progression, including aggressiveness, disease-free survival, and overall survival in patients with pancreatic ductal adenocarcinoma[15]. Recent studies have also demonstrated that multiparametric magnetic resonance (MR) imaging (MRI) as a standard of pre-biopsy care has increased the prostate cancer detection rate from 26% to 38% [16]. Medical image texture analysis is utilized to quantitatively extract features not discernible to the naked eye, further reflecting the distribution pattern and changes in pixel gray values in the ROI, aiding in the identification of potential heterogeneity in tumor lesions[17].

In this study, our goal is to acquire quantitative features from the ROI using a high-throughput method and forecast MVI in HCC through texture analysis based on MRI. We aim to offer an objective auxiliary method for noninvasive preoperative prediction of MVI in HCC, potentially guiding clinical decisions.

Zaishidena® WJGO https://www.wjgnet.com

MATERIALS AND METHODS

From June 2016 to March 2022, 105 eligible HCC patients from our hospital were enrolled in this study. Patients were categorized into the MVI-positive group (57 cases) and the MVI-negative group (48 cases) based on postoperative pathological results. Inclusion criteria for the study were: (1) Pathologically confirmed HCC; (2) age \geq 18 years; (3) plain liver MRI scan and three-phase enhanced scan conducted 2 wk before surgery; and (4) completion of at least two cycles of chemotherapy. Exclusion criteria included: (1) Non-primary central nervous system lymphoma; (2) previous treatment with other BTK inhibitors; and (3) a single HCC lesion. Additionally, none of the patients had undergone any tumor-related treatment prior to surgery.

All procedures involving human participants were in accordance with the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of The Third Affiliated Hospital of Guangxi Medical University. All patients provided written informed consent for their participation.

Grouping

Following the methodology of Rodríguez-Perálvarez *et al*[18], patients were grouped into MVI-positive and MVI-negative categories based on their postoperative pathological diagnosis of MVI. The diagnostic criteria for this study were: The presence of tumor emboli in the portal vein, hepatic vein, or large blood vessels, as opposed to tumors in the small bile ducts of the surrounding liver tissue.

Image acquisition

Preparation before MRI scan and enhanced examination: Patients were required to fast for 4 h before the examination to ensure an empty stomach.

Prior to the examination, patients were instructed on the breath-holding process to minimize breathing motion artifacts during the scan, and were asked to remove all metal objects. Patients with no contraindications for MRI examinations had an indwelling needle placed in their forearm by a nurse.

Liver MRI routine sequence and parameter settings: SIEMENS Verio 3.0T was used with the following parameters: Axial T1 VIBE FSTRA P2 HB 320 (TR/TE 3.92/1.39 ms), slice thickness 4 mm; Axial T2 BLADE TRA FS P2 TRIG 320 (TR/TE 4185.31/89.00 ms), layer thickness 6 mm. A bolus injection of gadopentetate dimeglumine (Gd-DTPA; 0.2 mmol/kg) was administered for enhanced scanning *via* the cubital vein using a dual-barrel high-pressure syringe at a preset flow rate of 2.0 mL/s. Sterile saline (20 mL of 0.9% solution) was injected to flush the tubes. The arterial, portal venous, and equilibrium phases were scanned at 15-20 s, 50-55 s, and 85-90 s after the contrast agent injection, respectively. The selected MR images were exported from the PACS system in BMP format.

ROI outline and texture feature extraction

MaZda4.6 software (http://www.eletel.p.lod14z.pl/mazda/) was utilized as follows: Firstly, a radiologist identified the contrast-enhanced scan phase with the clearest lesion boundary in each HCC patient, manually drawing it layer by layer and merging it into the volume area of interest (VOI), which was then copied onto the MR image of the enhanced scanning sequence. Secondly, the ROI was manually outlined layer by layer and merged into the VOI, accounting for differences in image layer thickness and enhanced images in the T2-weighted imaging (T2WI) sequence. Finally, a senior radiologist verified the placement of all ROIs layer by layer. If there were any issues with the ROI delineation or VOI registration, the lesions were re-delineated or registered until consensus was reached. To minimize the impact of the local volume effect, the ROI was manually outlined within 1-2 mm of the tumor on all slices. Additionally, grayscale normalization was applied to all included MR images using MaZda4.6 to minimize image errors due to patient-specific conditions or variations in scanning personnel before extracting texture features[14].

Feature dimensionality reduction and computer-automatic discrimination based on B11 program

To avoid excessive redundancy in texture features, the 10 most significant texture features were identified using Fisher, POE + ACC, MI, and MI + PA + F through texture feature screening (feature dimension reduction), by MaZda4.6 software. The PA + F feature dimensionality reduction method identified the top 30 texture features with the most significance for subsequent automatic classification and discrimination by a computer. Subsequently, the classification methods Redundancy Analysis, Principal Component Analysis, Linear Discriminant Analysis (LDA), and Non-LDA (NDA), included in the MaZda4.6 software's B11 program, were employed to automatically distinguish HCC in different MVI groups and calculate the misjudgment rate (MCR) based on these optimal discriminant features. MCR (%) = (total number of misjudged cases/total number of cases identified in different groups) × 100 (The VOI generated from the texture analysis based on the MR image, along with the extracted 3D texture features, are illustrated in Figure 1. and the workflow of texture analysis based on MR images was depicted in Figure 2).

Statistical analysis

Meta-analyses were performed using SPSS 19.0 and MaZda4.6 software. Results are presented as mean \pm SD. Textural parameters between the two groups were compared using the independent sample Mann–Whitney *U*-test. Receiver operating characteristic (ROC) analyses were conducted to evaluate the diagnosis of MVI. A *P* value < 0.05 was considered statistically significant.

Raisbideng® WJGO | https://www.wjgnet.com




Figure 1 The volume area of interest generated from the texture analysis based on the magnetic resonance image, along with the extracted 3D texture features. The figure includes extraction of 94 diverse texture features from the volume area of interest (VOI) and a reporting window that details the VOI placement and texture feature extraction process (such as basic image details, types of texture features, specific texture characteristics, and their corresponding parameter values).

RESULTS

The baseline characteristics of patients with HCC

Between June 2016 and March 2022, 105 eligible HCC patients were included in this study. The cohort consisted of 13 females and 92 males, with a median age of 52.97 years (range 29-80 years). Patients were categorized into MVI-positive [57 cases; 50 males and 7 females; median age 51.35 ± 12.565 years (range 29-80)] and MVI-negative [48 cases; 42 males and 6 females; median age 54.90 ± 10.896 years (range 35-79)] groups based on postoperative pathological results (details showed in Table 1).

The texture analysis in the diagnosis of HCC

The combination of MI + PA + F and NDA in texture analysis based on MR images demonstrated the most effective prediction for HCC MVI. The MCRs were 22.86%, 16.19%, 20.95%, and 20.95%, respectively (details were presented in Table 2, and the visualization of the predicted results based on MR arterial phase image analysis was shown in Figure 3).

The ROC analysis of HCC

The ROC curve depicting the positive prediction of MVI in HCC using the texture analysis combination of MI + PA + F and NDA, specifically based on arterial phase MR images, was shown in Figure 4. This method also demonstrated high accuracy (lower MCR) in predicting MVI in HCC, particularly when based on arterial phase images. The prediction accuracy was 83.81%, with an area under the curve (AUC) for predicting MVI in HCC of 0.844, a sensitivity of 77.19%, and a specificity of 91.67% (Table 3 and Figure 2).

DISCUSSION

MVI is a crucial risk factor for tumor recurrence and metastasis following HCC surgery. The occurrence of MVI is common across all stages of HCC, resulting from the combined action of multiple factors[19]. Preoperative prediction of MVI in HCC plays a significant role in treatment selection and prognosis evaluation [3,4,20]. Currently, the preoperative



Zaishideng® WJGO | https://www.wjgnet.com

Table 1 The Baseline characteristics of patients with hepatocellular carcinoma						
	MVI negative group (<i>n</i> = 48)	MVI positive group (<i>n</i> = 57)	Τ/χ ²	P value		
Age (yr)	54.90 ± 10.896	51.35 ± 12.565	-1.529	0.129		
Gender						
Male	42	50	0.001	0.973		
Female	6	7				

 T/χ^2 : Comparison of *t*-test chi-square test. MVI: Microvascular invasion.

Extraction method	Parameters
Grayscale histogram (9)	Mean, variance, skewness, kurtosis, and percentiles (1%, 10%, 50%, 90%, and 99%)
Grayscale co-occurrence matrix (55)	Angular second order distance, correlation, contrast, entropy, entropy sum, square sum, mean sum, mean difference, inverse distance, entropy difference, standard deviation
Grayscale gradient (5)	Average gradient, gradient variance, gradient skewness, gradient kurtosis, non-zero gradient
Long run matrices (25)	(Horizontal, vertical, 0°, 45°, 135°) Run length non-uniformity, gray value non-uniformity, long run enhancement, short run enhancement, fractional run

Table 3 The misiud	ament rate (%) of mag	netic resonance ima	de-base	d texture analysis

MR image	Project	Fisher	POE + ACC	MI	MI + PA + F
T2WI	RDA	57/105 (or 54.29)	57/105 (or 54.29)	59/105 (or 56.19)	50/105 (or 47.62)
12,111		, , ,		, , ,	
	PCA	52/105 (or 49.52)	57/105 (or54.29)	57/105 (or 54.29)	58/105 (or 55.24)
	LDA	46/105 (or 43.81)	46/105 (or43.81)	47/105 (or 44.76)	34/105 (or 32.38)
	NDA	26/105 (or 24.76)	27/105 (or25.71)	29/105 (or 27.62)	24/105 (or 22.86)
Arterial phase	RDA	44/105 (or 41.90)	52/105 (or49.52)	38/105 (or 36.19)	49/105 (or 46.67)
	PCA	46/105 (or 43.81)	52/105 (or49.52)	39/105 (or 37.14)	49/105 (or 46.67)
	LDA	41/105 (or 39.05)	36/105 (or34.29)	46/105 (or 43.81)	34/105 (or 32.38)
	NDA	22/105 (or 20.95)	23/105 (or21.90)	25/105 (or 23.81)	17/105(or16.19))
Portal phase	RDA	41/105 (or 39.05)	46/105 (or43.81)	48/105 (or 45.71)	38/105 (or 36.19)
	PCA	41/105 (or 39.05)	41/105 (or39.05)	48/105 (or 45.71)	38/105 (or 36.19)
	LDA	45/105 (or 42.86)	48/105 (or45.71)	42/105 (or 40.00)	32/105 (or 30.48)
	NDA	32/105 (or 30.48)	28/105 (or26.67)	33/105 (or 31.43)	22/105 (or 20.95)
Equilibrium period	RDA	43/105 (or 40.95)	56/105 (or53.33)	42/105 (or 40.00)	48/105 (or 45.71)
	PCA	42/105 (or 40.00)	55/105 (or52.38)	45/105 (or 42.86)	42/105 (or 40.00)
	LDA	49/105 (or 46.67)	42/105 (or40.00)	45/105 (or 42.86)	34/105 (or 32.38)
	NDA	28/105 (or 26.67)	23/105 (or21.90)	27/105 (or 25.71)	22/105 (or 20.95)

MR: Magnetic resonance; RDA: Redundancy Analysis; PCA: Principal Component Analysis; LDA: Linear Discriminant Analysis; NDA: Non- Linear Discriminant Analysis; T2WI: T2-weighted imaging.

assessment of HCC MVI primarily relies on semantic features of multiphase CT and enhanced MRI. These include smoothness of the tumor margin, larger tumor size (> 5 cm in diameter), peritumoral arterial enhancement, lack of enhanced capsule, low tumor signal, all of which possess a degree of subjectivity and lack objective and repeatable measurement indices[21-24]. The predictive capabilities of functional imaging modalities, such as imaging diffusion kurtosis, diffusion-weighted imaging, and positron emission tomography-CT, require improvement due to their instability and lack of reproducibility[25-27]. Liver texture analysis has been reported to aid in predicting the nature of




Figure 2 The workflow of texture analysis based on magnetic resonance images. VOI: Volume area of interest; MV: Microvascular.

intrahepatic lesions, classifying HCC lesions, and forecasting treatment prognosis[28]. Dynamic contrast-enhanced MRI image texture analysis technology is beneficial for preoperative prediction of MVI, showing higher prediction accuracy [29]. Consequently, it is essential to further explore objective quantitative methods for more accurate preoperative of MVI prediction in HCC.

In this study, we expanded our analysis to include multi-parametric MR-enhanced images for texture analysis, encompassing images of MR-T2WI, arterial phase, portal venous phase, and equilibrium phase. The MCRs were 22.86%, 16.19%, 20.95%, and 20.95%, respectively, demonstrating high accuracy (lower MCRs) in predicting MVI of HCC, particularly the arterial phase images. The prediction accuracy was 83.81%, with an AUC of 0.844, a sensitivity of 77.19%, and a specificity of 91.67%. These results were similar to those reported by Liu *et al*[30], suggesting the texture quantification based on MR images was a viable method for predicting MVI in HCC[30]. Liu *et al*[30] developed a binary logistic regression prediction model based on MR arterial phase texture features combined with imaging features. The AUC, sensitivity, and specificity for predicting MVI in HCC were 0.810, 0.811, and 0.790, respectively. This study determined that the combination of MI + PA + F and NDA texture analysis, specifically based on MR arterial phase images, had the most effective prediction for HCC MVI.

The contribution of the hepatic arterial system to tumor supply becomes increasingly apparent and gradually dominates the development and progression of HCC. Consequently, the texture features of arterial phase images can more accurately characterize tumor progression. When MVI exists in HCC, the local hemodynamics around the tumor are more pronounced compared to the venous phase. Moreover, this study showed better performance using arterial and equilibrium phase images compared to MR-T2WI and portal venous phase, aligning with the findings of Zhu *et al*[31]. However, this study deviates from previous ones[32,33], where some have indicated that radiomic sores of the portal venous phase surpass those of the arterial or equilibrium phases. This could be attributed to selection bias and inclusion criteria. Nonetheless, texture analysis based on enhanced CT and MRI requires further validation for predicting HCC progression. Currently, there are limited studies comparing the efficacy of texture analysis based on CT and MR images for predicting MVI in HCC, necessitating further research.

WJGO https://www.wjgnet.com




Figure 3 The visualization of the predicted results based on magnetic resonance arterial phase image analysis. A: The log grayscale analysis; B: The MEF grayscale analysis; C: The MDF grayscale analysis; D: The Non-Linear Discriminant Analysis.




Figure 4 Receiver operating characteristic curve analysis based on binomial logistic regression analysis. ROC: Receiver operating characteristic; AUC: Area under the curve.

Study limitations

This study had several limitations. Firstly, the images utilized were acquired by multiple scanning technicians. To mitigate the impact of the diversity in MR scanning personnel, the variability in patient conditions, and the lack of standardization in MRI, all images underwent grayscales normalization before texture feature extraction. However, future applications and development of artificial intelligence in this field will need to address the challenges posed by multi-center equipment. Thus, optimizing algorithms and conducting multicenter's research and analysis are imperative for future advancements. Secondly, this study focused solely on comparing the identification capabilities of texture analysis based on MRI-T2WI and three-phase enhanced scanning MRI, without a comprehensive examination and comparison of clinically relevant data and imaging manifestations. The employed high-degree evaluation method aligns with the requirements for a comprehensive clinical assessment. Future research in this area should involve expanding the sample size to achieve higher predictive accuracy and identify more practical methods. Thirdly, the use of a 3D ROI may



Raishideng® WJGO | https://www.wjgnet.com

introduce some subjectivity due to manual delineation. Lastly, retrospective studies are more susceptible to bias and confounding variables, which can lead to incorrect conclusions. Future studies should focus on utilizing automatic delineation and larger datasets to mitigate these issues.

CONCLUSION

This study demonstrated that textural features based on multi-parametric MR images are reliable predictors of vascular invasion in HCC. Specifically, the MI + PA + F of arterial phase images, in conjunction with NDA texture analysis, might aid in selecting optimal choice of therapeutic approaches. However, further large-scale studies are necessary to validate these findings.

ARTICLE HIGHLIGHTS

Research background

The study aims to provide an objective, non-invasive method for the hepatocellular carcinoma (HCC) prediction, addressing the limitations of current assessment methods that are invasive and carry risks. It seeks to validate the use of texture analysis in magnetic resonance (MR) imaging (MRI) as a reliable predictive tool for microvascular invasion (MVI), potentially guiding clinical decisions and improving poor patient outcomes in HCC.

Research motivation

The primary motivation is to enhance preoperative MVI prediction in HCC, which is crucial for selecting appropriate treatment plans.

Research objectives

The main objective of the study was to assess the effectiveness of texture analysis based on multi-parametric MR images in predicting MVI of HCC. The goal was to provide a non-invasive, objective method to aid in the preoperative prediction of MVI, thereby valuable information for treatment planning and prognosis evaluation in HCC patients.

Research methods

The study employed a retrospective analysis approach, including 105 patients with pathologically confirmed HCC. It used texture analysis methods such as original data analysis, principal component analysis, linear discriminant analysis (LDA), and non-LDA on multi-parametric MR images. The effectiveness of these methods was evaluated using the misjudgment rate derived from the MaZda4.6 software. This approach allowes for a detailed quantitative analysis of the MR images, offering novel insights into the potential of texture analysis in medical imaging.

Research results

The study found that texture analysis of arterial phase images from multi-parametric MRI was highly effective in predicting MVI in HCC. The combination of MI + PA + F dimensionality reduction method and nonlinear discriminant analysis showed the highest prediction accuracy. These results contribute significantly to the field by offering a noninvasive, objective predictive tool for MVI in HCC, potentially improving treatment decisions. However, the need for larger, prospective studies to validate these findings, highlighting a key area for future research in this domain.

Research conclusions

This study introduced new methods for predicting MVI in HCC using texture analysis of multi-parametric MR images. It proposed the combination of MI + PA + F dimensionality reduction and nonlinear discriminant analysis as a novel and effective approach. This methodology represents a significant advancement in non-invasive, objective diagnostic tool in the field of HCC management.

Research perspectives

Future research should focus on validating the efficacy of texture analysis in larger, multicenter studies, exploring its integration with other diagnostic modalities to enhance MVI prediction accuracy in HCC. Additionally, investigating the applicability of this method in other types of cancer could broaden its clinical significance and utility.

FOOTNOTES

Co-corresponding authors: Man-Rong Liu and Ke Ding.

Author contributions: Nong HY, Ding K, Cen YY, and Qin M carried out the studies, participated in collecting data, and drafted the manuscript; Ding K, Liu MR, Nong HY, and Li L performed the statistical analysis and participated in its design; Qin WQ and Xie YX helped to draft the manuscript; all authors read and approved the final manuscript. Liu MR and Ding K contributed equally to this study



and serve as co-corresponding authors of this study.

Supported by National Natural Science Foundation of China, No. 81560278; and the Health Commission of Guangxi Zhuang Autonomous Region, No. Z-A20221157, No. Z20200953, and No. G201903023.

Institutional review board statement: The study protocol was approved by the Ethics Committees of The Third Affiliated Hospital of Guangxi Medical University.

Informed consent statement: All the patients provided written informed consent for participation.

Conflict-of-interest statement: There are no conflicts of interest to report.

Data sharing statement: No additional data are available.

STROBE statement: The authors have read the STROBE Statement - checklist of items, and the manuscript was prepared and revised according to the STROBE Statement - checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Ke Ding 0000-0002-8987-1704.

S-Editor: Lin C L-Editor: A P-Editor: Zhang XD

REFERENCES

- 1 Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, Park JW. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. J Hepatol 2021; 74: 603-612 [PMID: 33031846 DOI: 10.1016/j.jhep.2020.09.026]
- Chen M, Shu G, Lv X, Xu X, Lu C, Qiao E, Fang S, Shen L, Zhang N, Wang J, Chen C, Song J, Liu Z, Du Y, Ji J. HIF-2α-targeted 2 interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma. Biomaterials 2022; 284: 121512 [PMID: 35405577 DOI: 10.1016/j.biomaterials.2022.121512]
- Expert consensus on multidisciplinary diagnosis and treatment of precancerous lesions of hepatocellular carcinoma (2020 edition). Zhonghua 3 Gan Zang Bing Za Zhi 2020; 28: 14-20 [PMID: 32023692 DOI: 10.3760/cma.j.issn.1007-3418.2020.01.005]
- Nitta H, Allard MA, Sebagh M, Ciacio O, Pittau G, Vibert E, Sa Cunha A, Cherqui D, Castaing D, Bismuth H, Guettier C, Lewin M, Samuel 4 D, Baba H, Adam R. Prognostic Value and Prediction of Extratumoral Microvascular Invasion for Hepatocellular Carcinoma. Ann Surg Oncol 2019; 26: 2568-2576 [PMID: 31054040 DOI: 10.1245/s10434-019-07365-0]
- 5 Chen ZH, Zhang XP, Wang H, Chai ZT, Sun JX, Guo WX, Shi J, Cheng SQ. Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis. HPB (Oxford) 2019; 21: 935-944 [PMID: 30871805 DOI: 10.1016/j.hpb.2019.02.003
- Sun R, Zhao S, Jiang H, Dai Y, Zhang C, Wang S. Imaging Tool for Predicting Renal Clear Cell Carcinoma Fuhrman Grade: Comparing 6 R.E.N.A.L. Nephrometry Score and CT Texture Analysis. Biomed Res Int 2021; 2021: 1821876 [PMID: 34977234 DOI: 10.1155/2021/1821876]
- Feng M, Zhang M, Liu Y, Jiang N, Meng Q, Wang J, Yao Z, Gan W, Dai H. Texture analysis of MR images to identify the differentiated 7 degree in hepatocellular carcinoma: a retrospective study. BMC Cancer 2020; 20: 611 [PMID: 32605628 DOI: 10.1186/s12885-020-07094-8]
- López-Gómez C, Ortiz-Ramón R, Mollá-Olmos E, Moratal D; Alzheimer's Disease Neuroimaging Initiative. ALTEA: A Software Tool for the 8 Evaluation of New Biomarkers for Alzheimer's Disease by Means of Textures Analysis on Magnetic Resonance Images. Diagnostics (Basel) 2018; 8 [PMID: 30029524 DOI: 10.3390/diagnostics8030047]
- Giganti F, Antunes S, Salerno A, Ambrosi A, Marra P, Nicoletti R, Orsenigo E, Chiari D, Albarello L, Staudacher C, Esposito A, Del Maschio 9 A, De Cobelli F. Gastric cancer: texture analysis from multidetector computed tomography as a potential preoperative prognostic biomarker. Eur Radiol 2017; 27: 1831-1839 [PMID: 27553932 DOI: 10.1007/s00330-016-4540-y]
- Li Y, Xu X, Weng S, Yan C, Chen J, Ye R. CT Image-Based Texture Analysis to Predict Microvascular Invasion in Primary Hepatocellular 10 Carcinoma. J Digit Imaging 2020; 33: 1365-1375 [PMID: 32968880 DOI: 10.1007/s10278-020-00386-2]
- Bakr S, Echegaray S, Shah R, Kamaya A, Louie J, Napel S, Kothary N, Gevaert O. Noninvasive radiomics signature based on quantitative 11 analysis of computed tomography images as a surrogate for microvascular invasion in hepatocellular carcinoma: a pilot study. J Med Imaging (Bellingham) 2017; 4: 041303 [PMID: 28840174 DOI: 10.1117/1.JMI.4.4.041303]
- 12 Ni M, Zhou X, Lv Q, Li Z, Gao Y, Tan Y, Liu J, Liu F, Yu H, Jiao L, Wang G. Radiomics models for diagnosing microvascular invasion in hepatocellular carcinoma: which model is the best model? Cancer Imaging 2019; 19: 60 [PMID: 31455432 DOI: 10.1186/s40644-019-0249-x]
- Ma X, Wei J, Gu D, Zhu Y, Feng B, Liang M, Wang S, Zhao X, Tian J. Preoperative radiomics nomogram for microvascular invasion 13 prediction in hepatocellular carcinoma using contrast-enhanced CT. Eur Radiol 2019; 29: 3595-3605 [PMID: 30770969 DOI: 10.1007/s00330-018-5985-y]
- 14 Wieczorek-Pastusiak J, Kociński M, Raźniewski M, Strzelecki M, Stefańczyk L, Majos A. An attempt toward objective assessment of brain



WJGO | https://www.wjgnet.com

tumor vascularization using susceptibility weighted imaging and dedicated computer program - a preliminary study. Pol J Radiol 2013; 78: 50-56 [PMID: 23493465 DOI: 10.12659/PJR.883767]

- 15 Gao J, Huang X, Meng H, Zhang M, Zhang X, Lin X, Li B. Performance of Multiparametric Functional Imaging and Texture Analysis in Predicting Synchronous Metastatic Disease in Pancreatic Ductal Adenocarcinoma Patients by Hybrid PET/MR: Initial Experience. Front Oncol 2020; 10: 198 [PMID: 32158690 DOI: 10.3389/fonc.2020.00198]
- Patel N, Henry A, Scarsbrook A. The value of MR textural analysis in prostate cancer. Clin Radiol 2019; 74: 876-885 [PMID: 30573283 DOI: 16 10.1016/j.crad.2018.11.007]
- Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. Radiology 2016; 278: 563-577 [PMID: 17 26579733 DOI: 10.1148/radiol.2015151169]
- Rodríguez-Perálvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in 18 hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol 2013; 20: 325-339 [PMID: 23149850 DOI: 10.1245/s10434-012-2513-1]
- Costentin CE, Ferrone CR, Arellano RS, Ganguli S, Hong TS, Zhu AX. Hepatocellular Carcinoma with Macrovascular Invasion: Defining the 19 Optimal Treatment Strategy. Liver Cancer 2017; 6: 360-374 [PMID: 29234639 DOI: 10.1159/000481315]
- Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014; 63: 844-855 [PMID: 24531850 20 DOI: 10.1136/gutjnl-2013-306627]
- Ryu T, Takami Y, Wada Y, Tateishi M, Hara T, Yoshitomi M, Momosaki S, Yasumori K, Saitsu H, Okuda K. A Clinical Scoring System for 21 Predicting Microvascular Invasion in Patients with Hepatocellular Carcinoma Within the Milan Criteria. J Gastrointest Surg 2019; 23: 779-787 [PMID: 30788712 DOI: 10.1007/s11605-019-04134-y]
- Kim AY, Sinn DH, Jeong WK, Kim YK, Kang TW, Ha SY, Park CK, Choi GS, Kim JM, Kwon CHD, Joh JW, Kim MJ, Sohn I, Jung SH, 22 Paik SW, Lee WJ. Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma. J Hepatol 2018; 68: 1144-1152 [PMID: 29410377 DOI: 10.1016/j.jhep.2018.01.024]
- Huang M, Liao B, Xu P, Cai H, Huang K, Dong Z, Xu L, Peng Z, Luo Y, Zheng K, Peng B, Li ZP, Feng ST. Prediction of Microvascular 23 Invasion in Hepatocellular Carcinoma: Preoperative Gd-EOB-DTPA-Dynamic Enhanced MRI and Histopathological Correlation. Contrast Media Mol Imaging 2018; 2018: 9674565 [PMID: 29606926 DOI: 10.1155/2018/9674565]
- 24 Ariizumi S, Kitagawa K, Kotera Y, Takahashi Y, Katagiri S, Kuwatsuru R, Yamamoto M. A non-smooth tumor margin in the hepatobiliary phase of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging predicts microscopic portal vein invasion, intrahepatic metastasis, and early recurrence after hepatectomy in patients with hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2011; **18**: 575-585 [PMID: 21360083 DOI: 10.1007/s00534-010-0369-y]
- Bakr S, Gevaert O, Patel B, Kesselman A, Shah R, Napel S, Kothary N. Interreader Variability in Semantic Annotation of Microvascular 25 Invasion in Hepatocellular Carcinoma on Contrast-enhanced Triphasic CT Images. Radiol Imaging Cancer 2020; 2: e190062 [PMID: 32550600 DOI: 10.1148/rycan.2020190062]
- Ahn SY, Lee JM, Joo I, Lee ES, Lee SJ, Cheon GJ, Han JK, Choi BI. Prediction of microvascular invasion of hepatocellular carcinoma using 26 gadoxetic acid-enhanced MR and (18)F-FDG PET/CT. Abdom Imaging 2015; 40: 843-851 [PMID: 25253426 DOI: 10.1007/s00261-014-0256-0]
- Xu P, Zeng M, Liu K, Shan Y, Xu C, Lin J. Microvascular invasion in small hepatocellular carcinoma: is it predictable with preoperative 27 diffusion-weighted imaging? J Gastroenterol Hepatol 2014; 29: 330-336 [PMID: 24033853 DOI: 10.1111/jgh.12358]
- Chaudhary K, Poirion OB, Lu L, Garmire LX. Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer. 28 Clin Cancer Res 2018; 24: 1248-1259 [PMID: 28982688 DOI: 10.1158/1078-0432.CCR-17-0853]
- Ma XH, Zhu YJ, Wang S, Feng B, Wang Q, Kong Y, Zhao XM. Value of contrast-enhanced MRI texture analysis in predicting microvascular 29 invasion of primary hepatocellular carcinoma before operation. Zhonghua Fangshexue Zazhi 2018; 52: 327-332 [DOI: 10.3760/cma.j.issn.1005-1201.2018.05.002]
- Liu JP, Cheng DL, Liao YT, Zhang X, Lin SQ, Chen HW, Huang HM, Gao MY. To Explore the Preliminary Value of Predicting 30 Microvascular Invasion of Hepatocellular Carcinama Based on MR-T2WI Texture Analysis. Linchuang Fangshexue Zazhi 2021; 40: 1625-1628
- Zhu YJ, Feng B, Wang S, Wang LM, Wu JF, Ma XH, Zhao XM. Model-based three-dimensional texture analysis of contrast-enhanced 31 magnetic resonance imaging as a potential tool for preoperative prediction of microvascular invasion in hepatocellular carcinoma. Oncol Lett 2019; 18: 720-732 [PMID: 31289547 DOI: 10.3892/ol.2019.10378]
- Yao W, Yang S, Ge Y, Fan W, Xiang L, Wan Y, Gu K, Zhao Y, Zha R, Bu J. Computed Tomography Radiomics-Based Prediction of 32 Microvascular Invasion in Hepatocellular Carcinoma. Front Med (Lausanne) 2022; 9: 819670 [PMID: 35402463 DOI: 10.3389/fmed.2022.819670]
- Zhang W, Yang R, Liang F, Liu G, Chen A, Wu H, Lai S, Ding W, Wei X, Zhen X, Jiang X. Prediction of Microvascular Invasion in 33 Hepatocellular Carcinoma With a Multi-Disciplinary Team-Like Radiomics Fusion Model on Dynamic Contrast-Enhanced Computed Tomography. Front Oncol 2021; 11: 660629 [PMID: 33796471 DOI: 10.3389/fonc.2021.660629]



WJGO | https://www.wjgnet.com



Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

